Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET

BACKGROUND: Primary and secondary drug resistance to imatinib and sunitinib in patients with gastrointestinal stromal tumors (GISTs) has led to a pressing need for new therapeutic strategies such as drug combinations. Most GISTs are caused by mutations in the KIT receptor, leading to upregulated KIT...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Pantaleo, Maria Abbondanza, Nicoletti, Giordano, Nanni, Cristina, Gnocchi, Chiara, Landuzzi, Lorena, Quarta, Carmelo, Boschi, Stefano, Nannini, Margherita, Di Battista, Monica, Castellucci, Paolo, Fanti, Stefano, Lollini, Pier Luigi, Bellan, Elena, Castelli, Mauro, Rubello, Domenico, Biasco, Guido
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2010
विषय:
Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3022678/
https://ncbi.nlm.nih.gov/pubmed/21192792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-9966-29-173
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन